Hayes Andrew J, Maynard Lauren, Coombes Gillian, Newton-Bishop Julia, Timmons Michael, Cook Martin, Theaker Jeffrey, Bliss Judith M, Thomas J Meirion
The Royal Marsden Hospital National Health Foundation Trust, London, UK.
Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, UK.
Lancet Oncol. 2016 Feb;17(2):184-192. doi: 10.1016/S1470-2045(15)00482-9. Epub 2016 Jan 12.
The necessary margin of excision for cutaneous melanomas greater than 2 mm in thickness is controversial. At a median follow-up of 5 years, findings from our previously published randomised trial of narrow (1 cm) versus wide (3 cm) excision margins in patients with thick cutaneous melanomas showed that narrow margins were associated with an increased frequency of locoregional relapse, but no significant difference in overall survival was apparent. We now report a long-term survival analysis of that trial.
We did a randomised, open-label multicentre trial in 59 hospitals--57 in the UK, one in Poland, and one in South Africa. Patients with one primary localised cutaneous melanoma greater than 2 mm in Breslow thickness on the trunk or limbs (excluding palms or soles) were randomly assigned (1:1) centrally to receive surgery with either a 1 cm or 3 cm excision margin following an initial surgery. The randomisation lists were generated with random permuted blocks and stratified by centre and extent of initial surgery. The endpoints of this analysis were overall survival and melanoma-specific survival. Analyses were done in the intention-to-treat population. This trial was not registered because it predated mandatory trial registration.
Between Dec 16, 1992, and May 22, 2001, we randomly assigned 900 patients to surgery with either a 1 cm excision margin (n=453) or a 3 cm excision margin (n=447). At a median follow-up of 8·8 years (106 months [IQR 76-135], 494 patients had died, with 359 of these deaths attributed to melanoma. 194 deaths were attributed to melanoma in the 1 cm group compared with 165 in the 3 cm group (unadjusted hazard ratio [HR] 1·24 [95% CI 1·01-1·53]; p=0·041). Although a higher number of deaths overall occurred in the 1 cm group compared with the 3 cm group (253 vs 241), the difference was not significant (unadjusted HR 1·14 [95% CI 0·96-1·36]; p=0·14). Surgical complications were reported in 35 (8%) patients in the 1 cm excision margin group and 65 (15%) patients in the 3 cm group.
Our findings suggest that a 1 cm excision margin is inadequate for cutaneous melanoma with Breslow thickness greater than 2 mm on the trunk and limbs. Current guidelines advise a 2 cm margin for melanomas greater than 2 mm in thickness but only a 1 cm margin for thinner melanomas. The adequacy of a 1 cm margin for thinner melanomas with poor prognostic features should be addressed in future randomised studies.
Cancer Research UK, North Thames National Health Service Executive, Northern and Yorkshire National Health Service Executive, British United Provident Association Foundation, British Association of Plastic Surgeons, the Meirion Thomas Cancer Research Fund, and the National Institute for Health and Research Biomedical Research Centre at The Royal Marsden NHS Foundation Trust.
厚度大于2mm的皮肤黑色素瘤的必要切除切缘存在争议。在我们之前发表的一项针对厚皮黑色素瘤患者进行窄切缘(1cm)与宽切缘(3cm)切除的随机试验中,中位随访5年的结果显示,窄切缘与局部区域复发频率增加相关,但总生存率无明显差异。我们现在报告该试验的长期生存分析结果。
我们在59家医院开展了一项随机、开放标签的多中心试验,其中57家在英国,1家在波兰,1家在南非。对躯干或四肢(不包括手掌或足底)上有一处Breslow厚度大于2mm的原发性局限性皮肤黑色素瘤患者,在初次手术后通过中央随机分组(1:1),使其接受切除切缘为1cm或3cm的手术。随机分组列表采用随机排列分组法生成,并按中心和初次手术范围进行分层。该分析的终点为总生存率和黑色素瘤特异性生存率。在意向性治疗人群中进行分析。由于该试验早于强制试验注册规定实施时间,因此未进行注册。
在1992年12月16日至2001年5月22日期间,我们将900例患者随机分配接受切除切缘为1cm(n = 453)或3cm(n = 447)的手术。中位随访8.8年(106个月[四分位间距76 - 135])时,494例患者死亡,其中359例死亡归因于黑色素瘤。1cm组有194例死亡归因于黑色素瘤,3cm组为165例(未调整风险比[HR] 1.24 [95%CI 1.01 - 1.53];p = 0.041)。尽管1cm组总体死亡人数高于3cm组(253例对241例),但差异无统计学意义(未调整HR 1.14 [95%CI 0.96 - 1.36];p = 0.14)。切除切缘为1cm组有35例(8%)患者报告有手术并发症,3cm组有65例(15%)患者出现手术并发症。
我们的研究结果表明,对于躯干和四肢上Breslow厚度大于2mm的皮肤黑色素瘤,1cm的切除切缘不足。当前指南建议,厚度大于2mm的黑色素瘤切缘为2cm,但厚度较薄的黑色素瘤切缘仅为1cm。对于预后特征较差的较薄黑色素瘤,1cm切缘是否足够,应在未来的随机研究中加以探讨。
英国癌症研究中心、北泰晤士国民保健服务执行局、北部和约克郡国民保健服务执行局、英国联合 Provident 协会基金会、英国整形外科医生协会、Meirion Thomas 癌症研究基金以及皇家马斯登国民保健服务信托基金会的国家卫生与研究生物医学研究中心。